Vestal Point Capital LP reduced its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 18.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 490,000 shares of the company's stock after selling 110,000 shares during the period. Vestal Point Capital LP owned about 0.90% of Voyager Therapeutics worth $2,866,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock worth $30,087,000 after buying an additional 702,030 shares in the last quarter. American International Group Inc. boosted its holdings in Voyager Therapeutics by 22.9% in the first quarter. American International Group Inc. now owns 19,397 shares of the company's stock valued at $181,000 after purchasing an additional 3,610 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Voyager Therapeutics by 95.3% in the first quarter. Lazard Asset Management LLC now owns 18,742 shares of the company's stock valued at $174,000 after purchasing an additional 9,146 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company's stock valued at $9,702,000 after purchasing an additional 37,144 shares in the last quarter. Finally, Plato Investment Management Ltd purchased a new stake in Voyager Therapeutics during the 1st quarter worth approximately $38,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.
Voyager Therapeutics Stock Up 18.7 %
VYGR stock traded up $1.08 during midday trading on Friday, reaching $6.86. The company had a trading volume of 1,190,212 shares, compared to its average volume of 637,878. The firm has a market capitalization of $374.76 million, a PE ratio of 9.44 and a beta of 0.89. The stock has a 50 day moving average price of $6.50 and a 200 day moving average price of $7.32. Voyager Therapeutics, Inc. has a fifty-two week low of $5.19 and a fifty-two week high of $11.72.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the firm posted ($0.59) EPS. Research analysts predict that Voyager Therapeutics, Inc. will post -1.03 EPS for the current year.
Analyst Ratings Changes
VYGR has been the subject of several research analyst reports. StockNews.com upgraded Voyager Therapeutics from a "hold" rating to a "buy" rating in a research note on Monday, November 18th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Wedbush initiated coverage on Voyager Therapeutics in a research note on Friday. They issued an "outperform" rating and a $11.00 price target for the company. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $17.50.
Check Out Our Latest Research Report on Voyager Therapeutics
Insider Transactions at Voyager Therapeutics
In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.53% of the company's stock.
Voyager Therapeutics Company Profile
(
Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Read More
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.